In this audio brief, we unpack the practical implications of the FDA’s Final Guidance on Computer Software Assurance (CSA), issued September 2025.

The debate highlights two perspectives:

* Quality professional’s view: CSA cuts unnecessary documentation, aligns validation with patient safety risk, and supports agile manufacturing.

* Auditor’s view: CSA’s reliance on qualitative judgment, binary risk classification, and vendor dependence creates new challenges for audits, SOPs, and Part 11 compliance.

Key themes include:

* The distinction between CSA process risk vs. ISO 14971 medical device risk.

* The binary “high vs. not high process risk” classification and its audit implications.

* Use of unscripted testing (exploratory, scenario, error guessing) and the challenge of proving rigor.

* Vendor accountability in cloud/SaaS environments and continuous deployment.

* The cultural shift required for manufacturers to define and defend “profound judgment” in risk decisions.

Ultimately, CSA is framed as both an opportunity for efficiency and a test of organizational maturity in risk-based quality management.

🎧Listen to the audio brief above for an overview of the AI/ML device recalls, emerging vulnerabilities and trends to watch.

Thanks for reading Let's Talk Risk!. This post is public so feel free to share it.

Note:

This audio brief was prepared using Google NotebookLM, an AI-enabled research tool. Here is the list of resources used in our analysis:

* Computer Software Assurance for Production and Quality System Software, Final Guidance issued on September 24, 2025.

This summary was created using ChatGPT-5 with expert review. It distills publicly available information on the FDA’s Final Guidance on Computer Software Assurance (CSA). While reviewed for accuracy and relevance, it does not constitute legal, regulatory, or medical advice. Software assurance practices in healthcare are rapidly evolving, and details may change after publication.

We encourage listeners to interpret these findings in the context of these constraints.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe